Durata Therapeutics Priced, Nasdaq: DRTX
Developing Phase 3 antibiotic candidate for acute skin infections.
Industry: Health Care
First Day Return: +0.4%
DRTX
Developing Phase 3 antibiotic candidate for acute skin infections.
| IPO Data | |
|---|---|
| IPO Date | 07/18/2012 |
| Offer Price | IPO Intelligence Only |
| Price Range | IPO Intelligence Only |
| Offer Shares (mm) | IPO Intelligence Only |
| Deal Size ($mm) | $68 |
| Lock-Up Date | IPO Intelligence Only |
| Street Research | IPO Intelligence Only |
| Underwriters |
|---|
| IPO Intelligence Only |
| Company Data | |
|---|---|
| Headquarters | Morristown, NJ, United States |
| Founded | 2009 |
| Employees at IPO | 18 |
| Website www.duratatherapeutics.com | |
IPO News for Durata Therapeutics
Durata Therapeutics (DRTX) Performance
